FY2025 Earnings Forecast for FBIO Issued By HC Wainwright

Fortress Biotech, Inc. (NASDAQ:FBIO) – Analysts at HC Wainwright issued their FY2025 EPS estimates for Fortress Biotech in a research note issued on Tuesday, January 13th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will post earnings per share of ($0.20) for the year. The consensus estimate for Fortress Biotech’s current full-year earnings is ($3.28) per share. HC Wainwright also issued estimates for Fortress Biotech’s Q4 2025 earnings at $0.42 EPS, FY2026 earnings at $0.62 EPS and FY2027 earnings at $1.51 EPS.

Fortress Biotech (NASDAQ:FBIO) last announced its quarterly earnings data on Friday, November 14th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.54. The firm had revenue of $17.63 million for the quarter, compared to analyst estimates of $21.02 million. Fortress Biotech had a net margin of 6.40% and a negative return on equity of 69.39%.

A number of other equities analysts have also weighed in on FBIO. Zacks Research raised Fortress Biotech from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Wall Street Zen raised shares of Fortress Biotech from a “hold” rating to a “buy” rating in a research note on Sunday, November 23rd. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Fortress Biotech in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Fortress Biotech Stock Performance

Shares of Fortress Biotech stock opened at $3.72 on Thursday. The business has a 50-day simple moving average of $3.23 and a 200 day simple moving average of $2.80. Fortress Biotech has a one year low of $1.33 and a one year high of $4.53. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.19 and a quick ratio of 1.97. The firm has a market capitalization of $115.47 million, a price-to-earnings ratio of -20.67 and a beta of 1.42.

Institutional Trading of Fortress Biotech

Several institutional investors and hedge funds have recently made changes to their positions in FBIO. PFG Investments LLC boosted its holdings in Fortress Biotech by 22.4% during the second quarter. PFG Investments LLC now owns 55,419 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 10,160 shares during the last quarter. Shikiar Asset Management Inc. lifted its position in shares of Fortress Biotech by 18.0% during the 2nd quarter. Shikiar Asset Management Inc. now owns 278,469 shares of the biopharmaceutical company’s stock worth $518,000 after buying an additional 42,500 shares in the last quarter. 180 Wealth Advisors LLC boosted its stake in shares of Fortress Biotech by 6.4% in the 2nd quarter. 180 Wealth Advisors LLC now owns 93,050 shares of the biopharmaceutical company’s stock worth $173,000 after buying an additional 5,600 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Fortress Biotech in the second quarter valued at approximately $42,000. Finally, Panagora Asset Management Inc. purchased a new stake in shares of Fortress Biotech during the second quarter valued at approximately $93,000. Hedge funds and other institutional investors own 96.51% of the company’s stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.

Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies.